Arbeitsgruppe Pankreaskarzinom - Studien
| Pankreaskarzinom, metastasiert, 1st-line |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0317/ass: A multicenter randomized phase II/III study to determine the optimal first line chemotherapy regimen in medically fit patients diagnosed with metastatic pancreatic cancer (FOOTPATH) |
||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | zur Studie | |||
| AIO-PAK-0219: Intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled phase 3 trial (METAPANC) | ||||
| ---in Vorbereitung--- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0114: Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study (ALPACA) | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0118: A multi-center, phase I/II study of sequential epigenetic and immune targeting in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. (SEPION) |
||||
| ---in Vorbereitung --- | ||||
| AIO-Studie | für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-PAK-0120/xx:
MAintenance ThErapy vs. Observation in FOLFIRINOX treated metastatic Pancreatic
ductal adenocarcinoma patients - A prospective, randomized multi-center phase
II AIO trial (MATEO-Panc) |
||||
| ---in Vorbereitung --- | ||||
| Pankreaskarzinom – palliative Therapie, 2nd-line |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0216: Second- line therapy with Nal-IRI after failure of
gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of
first-line therapy - PREDICT |
||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-PAK-0116: A health service research study to
investigate survival of metastatic pancreatic cancer patients after sequential
chemotherapy: An AIO phase II cross over trial (PANTHEON) |
||||
| ---in Rekrutierung--- | ||||
| Pankreaskarzinom, local begrenzt, inoperabel |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| Randomisierte Phase-III-Studie zum Stellenwert einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom: Chemotherapie gefolgt von Radiochemotherapie im Vergleich zur alleinigen Chemotherapie - CONKO-007 | ||||
| ---in Rekrutierung--- | ||||
| Pankreaskarzinom - Operable Patienten |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-YMO/PAK-0218/ass - PROJECTION - Prognostic role of circulating tumor DNA in resectable pancreatic cancer | ||||
| ---in Vorbereitung--- | ||||
| AIO-assoziierte Studie | zur Studie | |||
| AIO-PAK-0121/ass - An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature - ESPAC-6 | ||||
| ---in Vorbereitung--- | ||||
| Pankreaskarzinom, neoadjuvant, perioperativ |
| AIO-assoziierte Studie | für weitere Zentren offen | zur Studie | ||
| AIO-PAK-0220/ass/xx:
Neoadjuvant treatment in frail patients with pancreatic adenocarcinoma - A
prospective, parallel-group, randomized multi-center Phase II AIO/CHIR-Net
Trial (FrailPanc) |
||||
| ---in Vorbereitung--- | ||||
| Registerstudie |
| AIO-Studie | für weitere Zentren offen |
zur Studie | ||
| AIO-YMO/PAK-0215 Eine multizentrische Registerstudie zur Erfassung klinischer, epidemiologischer und biologischer Parameter beim duktalen Adenokarzinom des Pankreas (PDAC, PaCaReg) | ||||
| ---in Rekrutierung--- | ||||
LETZTE AKTUALISIERUNG DIESER SEITE AM: 17.11.2020 |